title: Naproxen induces type X collagen expression in human bone-marrow-derived mesenchymal stem cells through the upregulation of 5-lipoxygenase.
abstract: Several studies have shown that type X collagen (COL X), a marker of late-stage chondrocyte hypertrophy, is expressed in mesenchymal stem cells (MSCs) from osteoarthritis (OA) patients. We recently found that Naproxen, but not other nonsteroidal anti-inflammatory drugs (NSAIDs) (Ibuprofen, Celebrex, Diclofenac), can induce type X collagen gene (COL10A1) expression in bone-marrow-derived MSCs from healthy and OA donors. In this study we determined the effect of Naproxen on COL X protein expression and investigated the intracellular signaling pathways that mediate Naproxen-induced COL10A1 expression in normal and OA hMSCs. MSCs of OA patients were isolated from aspirates from the intramedullary canal of donors (50-80 years of age) undergoing hip replacement surgery for OA and were treated with or without Naproxen (100 μg/mL). Protein expression and phosphorylation were determined by immunoblotting using specific antibodies (COL X, p38 mitogen-activated protein kinase [p38], phosphorylated-p38, c-Jun N-terminal kinase [JNK], phosphorylated-JNK, extracellular signal-regulated kinase [ERK], and phosphorylated-ERK). Real-time reverse transcription polymerase chain reaction (RT-PCR) was performed to determine the expression of COL10A1 and Runt-related transcription factor 2 gene (Runx2). Our results show that Naproxen significantly stimulated COL X protein expression after 72 h of exposure both in normal and OA hMSCs. The basal phosphorylation of mitogen-activated protein kinases (MAPKs) (ERK, JNK, and p38) in OA hMSCs was significantly higher than in normal. Naproxen significantly increased the MAPK phosphorylation in normal and OA hMSCs. NSAID cellular effects include cyclooxygenase, 5-lipoxygenase, and p38 MAPK signaling pathways. To investigate the involvement of these pathways in the Naproxen-induced COL10A1 expression, we incubated normal and OA hMSCs with Naproxen with and without inhibitors of ERK (U0126), JNK (BI-78D3), p38 (SB203580), and 5-lipoxygenase (MK-886). Our results showed that increased basal COL10A1 expression in OA hMSCs was significantly suppressed in the presence of JNK and p38 inhibitors, whereas Naproxen-induced COL10A1 expression was suppressed by 5-lipoxygenase inhibitor. This study shows that Naproxen induces COL X both at transcriptional and translational levels in normal and OA hMSCs. Elevated basal COL10A1 expression in OA hMSCs is probably through the activation of MAPK pathway and Naproxen-induced COL10A1 expression is through the increased 5-lipoxygenase signaling.
authors.affiliation: 1 Division of Orthopaedic Surgery, McGill University , Montreal, Canada .
authors.forename: Abdulrahman M
authors.initials: AM
authors.lastname: Alaseem
authors.forename: Padma
authors.initials: P
authors.lastname: Madiraju
authors.forename: Sultan A
authors.initials: SA
authors.lastname: Aldebeyan
authors.forename: Hussain
authors.initials: H
authors.lastname: Noorwali
authors.forename: John
authors.initials: J
authors.lastname: Antoniou
authors.forename: Fackson
authors.initials: F
authors.lastname: Mwale
mesh_terms: D000368:Aged; D001094:Arachidonate 5-Lipoxygenase / Q000235:genetics / Q000378:metabolism*; D016718:Arachidonic Acid / Q000378:metabolism; D001854:Bone Marrow Cells / Q000166:cytology*; D024121:Collagen Type X / Q000235:genetics* / Q000378:metabolism; D050659:Core Binding Factor Alpha 1 Subunit / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D059630:Mesenchymal Stem Cells / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D008875:Middle Aged; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D008954:Models, Biological; D009288:Naproxen / Q000494:pharmacology*; D010003:Osteoarthritis / Q000235:genetics / Q000473:pathology; D010766:Phosphorylation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D015854:Up-Regulation / Q000187:drug effects*
chemical_list: D024121:Collagen Type X; D050659:Core Binding Factor Alpha 1 Subunit; D047428:Protein Kinase Inhibitors; C493709:RUNX2 protein, human; D016718:Arachidonic Acid; D009288:Naproxen; D001094:Arachidonate 5-Lipoxygenase; D020928:Mitogen-Activated Protein Kinases
references.citation: J Biol Chem. 2001 Aug 24;276(34):31720-31
references.pmid: 11423555
references.citation: Osteoarthritis Cartilage. 2010 Nov;18(11):1509-17
references.pmid: 20813194
references.citation: J Biol Chem. 1984 Jun 10;259(11):6752-6
references.pmid: 6427221
references.citation: J Cell Biol. 2003 Sep 1;162(5):833-42
references.pmid: 12952936
references.citation: J Orthop Res. 2006 Aug;24(8):1791-8
references.pmid: 16779832
references.citation: J Pharm Pharm Sci. 2008 Sep 20;11(2):81s-110s
references.pmid: 19203472
references.citation: Mol Biol Rep. 2012 May;39(5):5683-9
references.pmid: 22183306
references.citation: Osteoarthritis Cartilage. 1999 Jul;7(4):374-6
references.pmid: 10419771
references.citation: Biochem Pharmacol. 2008 Oct 1;76(7):862-72
references.pmid: 18692027
references.citation: Nat Rev Rheumatol. 2009 Jun;5(6):309-16
references.pmid: 19491912
references.citation: Orthod Craniofac Res. 2005 Feb;8(1):11-7
references.pmid: 15667640
references.citation: Tissue Eng. 2006 Sep;12(9):2639-47
references.pmid: 16995797
references.citation: J Inflamm (Lond). 2008 Dec 04;5:22
references.pmid: 19055838
references.citation: PM R. 2012 May;4(5 Suppl):S10-9
references.pmid: 22632687
references.citation: Arthritis Rheum. 2003 Jun;48(6):1582-93
references.pmid: 12794826
references.citation: J Bone Miner Res. 2003 May;18(5):844-51
references.pmid: 12733723
references.citation: Am Rev Respir Dis. 1990 Jan;141(1):186-92
references.pmid: 2153353
references.citation: Arthritis Res Ther. 2010;12(1):R21
references.pmid: 20144213
references.citation: Z Rheumatol. 1999 Jun;58(3):125-9
references.pmid: 10441838
references.citation: Basic Clin Pharmacol Toxicol. 2014 Jan;114(1):70-7
references.pmid: 23953428
references.citation: Curr Opin Rheumatol. 2008 Sep;20(5):581-6
references.pmid: 18698181
references.citation: Histol Histopathol. 2009 Mar;24(3):347-66
references.pmid: 19130405
references.citation: Prostaglandins Other Lipid Mediat. 2003 Jul;71(3-4):147-62
references.pmid: 14518558
references.citation: Clin Orthop Relat Res. 2004 Oct;(427 Suppl):S145-51
references.pmid: 15480058
references.citation: Br J Clin Pharmacol. 1980 Sep;10(3):259-63
references.pmid: 7437243
references.citation: Arthritis Rheum. 2004 Dec;50(12):3925-33
references.pmid: 15593193
references.citation: Br Med Bull. 2013;105:185-99
references.pmid: 23337796
references.citation: J Immunol. 2009 Aug 15;183(4):2650-8
references.pmid: 19620296
references.citation: Ann Rheum Dis. 2011 Aug;70(8):1382-8
references.pmid: 21551506
references.citation: Tissue Eng Part A. 2010 Nov;16(11):3449-55
references.pmid: 20569194
references.citation: Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3213-8
references.pmid: 10725391
references.citation: J Biomed Mater Res A. 2005 Oct 1;75(1):216-23
references.pmid: 16044417
references.citation: Am J Physiol Regul Integr Comp Physiol. 2013 Dec;305(11):R1281-96
references.pmid: 24089379
references.citation: Biomaterials. 2006 Apr;27(10):2258-64
references.pmid: 16313952
references.citation: Biochem Pharmacol. 2003 Jul 15;66(2):289-95
references.pmid: 12826271
references.citation: Tissue Eng Part A. 2013 Apr;19(7-8):1039-46
references.pmid: 23231452
references.citation: Arthritis Rheum. 1992 Jul;35(7):806-11
references.pmid: 1622419
references.citation: J Pharmacol Exp Ther. 2007 Aug;322(2):453-60
references.pmid: 17473175
references.citation: Arthritis Res Ther. 2003;5(1):32-45
references.pmid: 12716446
references.citation: Ann Rheum Dis. 2009 Jun;68(6):938-47
references.pmid: 18653484
references.citation: Best Pract Res Clin Rheumatol. 2006 Feb;20(1):3-25
references.pmid: 16483904
references.citation: J Rheumatol. 2001 Nov;28(11):2509-19
references.pmid: 11708426
references.citation: Int J Biochem Cell Biol. 2008;40(1):46-62
references.pmid: 17659995
references.citation: Birth Defects Res C Embryo Today. 2008 Jun;84(2):131-54
references.pmid: 18546337
references.citation: Annu Rev Cell Dev Biol. 2013;29:63-79
references.pmid: 23725048
references.citation: Int J Biochem Cell Biol. 2006;38(10):1654-61
references.pmid: 16713323
references.citation: Biochem Pharmacol. 2005 Jul 1;70(1):30-6
references.pmid: 15894291
references.citation: Toxicol Appl Pharmacol. 2010 Jan 15;242(2):191-8
references.pmid: 19837106